This study enrolled 419 US adult participants that were randomised 1:1 to receive two doses of COVAXIN or placebo, 28 days apart. Blinded safety results and preliminary unblinded immunogenicity results are available through day 56, one month following the second vaccination. The top-line data from the immunobridging and broadening study will be critical to support Ocugen
